Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look".

Grette K, Long B, Finan MA, Rocconi RP.

Gynecol Oncol. 2019 Aug;154(2):290-293. doi: 10.1016/j.ygyno.2019.05.011. Epub 2019 May 31.

PMID:
31160072
2.

Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.

Skaznik-Wikiel ME, Lesnock JL, McBee WC, Beriwal S, Zorn KK, Richard SD, Krivak TC, Edwards RP.

Int J Gynecol Cancer. 2012 Feb;22(2):232-7. doi: 10.1097/IGC.0b013e318234f833.

PMID:
22080886
3.

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.

Gynecol Oncol. 2007 Jan;104(1):176-80. Epub 2006 Sep 25.

PMID:
16996584
4.

First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.

Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, Koshida T, Sawai H, Aotani E, Kohno I.

Gynecol Oncol. 2003 Sep;90(3):637-43. Erratum in: Gynecol Oncol. 2003 Dec;91(3):662.

PMID:
13678738
5.

A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.

Suidan RS, St Clair CM, Lee SJ, Barlin JN, Long Roche KC, Tanner EJ, Sonoda Y, Barakat RR, Zivanovic O, Chi DS.

Gynecol Oncol. 2014 Sep;134(3):468-72. doi: 10.1016/j.ygyno.2014.07.090. Epub 2014 Jul 17.

PMID:
25042672
6.

Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.

Mueller JJ, Kelly A, Zhou Q, Iasonos A, Long Roche K, Sonoda Y, O'Cearbhaill RE, Zivanovic O, Chi DS, Gardner GJ.

Gynecol Oncol. 2016 Dec;143(3):496-503. doi: 10.1016/j.ygyno.2016.09.014. Epub 2016 Sep 28.

7.

Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.

Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S.

Gynecol Oncol. 2012 Oct;127(1):51-4. doi: 10.1016/j.ygyno.2012.05.026. Epub 2012 May 30.

PMID:
22659193
8.

Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.

Miller EM, Tymon-Rosario J, Xie X, Xue X, Gressel GM, Miller DT, Kuo DY, Nevadunsky NS.

Gynecol Oncol. 2017 Oct;147(1):36-40. doi: 10.1016/j.ygyno.2017.07.129. Epub 2017 Jul 24.

PMID:
28751119
9.

Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.

Ghaemmaghami F, Karimi-Zarchi M, Modares-Gilani M, Mousavi A, Behtash N.

Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):719-24.

10.

Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.

Boisen MM, Lesnock JL, Richard SD, Beriwal S, Kelley JL, Zorn KK, Edwards RP.

Int J Gynecol Cancer. 2016 May;26(4):626-31. doi: 10.1097/IGC.0000000000000667.

PMID:
27051048
11.

Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.

Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC; Gynecologic Oncology Group.

Cancer. 2008 May 15;112(10):2202-10. doi: 10.1002/cncr.23390.

12.

Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.

Garcia-Soto AE, Java JJ, Nieves Neira W, Pearson JM, Cohn DE, Lele SB, Tewari KS, Walker JL, Alvarez Secord A, Armstrong DK, Copeland LJ.

Gynecol Oncol. 2016 Dec;143(3):484-489. doi: 10.1016/j.ygyno.2016.10.003. Epub 2016 Oct 7.

13.

What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD.

Cancer. 2017 May 15;123(6):985-993. doi: 10.1002/cncr.30414. Epub 2016 Nov 16.

14.

Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.

Gray HJ, Shah CA, Swensen RE, Tamimi HK, Goff BA.

Gynecol Oncol. 2010 Mar;116(3):340-4. doi: 10.1016/j.ygyno.2009.10.054. Epub 2009 Nov 17.

PMID:
19922987
15.

Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.

Schlappe BA, Mueller JJ, Zivanovic O, Gardner GJ, Long Roche K, Sonoda Y, Chi DS, O'Cearbhaill RE.

Gynecol Oncol. 2016 Jul;142(1):13-18. doi: 10.1016/j.ygyno.2016.05.015. Epub 2016 May 21. Erratum in: Gynecol Oncol. 2016 Oct;143(1):225.

16.

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.

Barlin JN, Dao F, Bou Zgheib N, Ferguson SE, Sabbatini PJ, Hensley ML, Bell-McGuinn KM, Konner J, Tew WP, Aghajanian C, Chi DS.

Gynecol Oncol. 2012 Jun;125(3):621-4. doi: 10.1016/j.ygyno.2012.03.027. Epub 2012 Mar 21.

PMID:
22446622
17.

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.

Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC.

Br J Cancer. 2013 Apr 2;108(6):1231-7. doi: 10.1038/bjc.2013.70. Epub 2013 Mar 5.

18.

Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?

Rocconi RP, Sullivan P, Long B, Blaize M, Brown J, Arbuckle J, Bevis K, Estes JM, Reed E, Finan MA.

Int J Gynecol Cancer. 2012 Jun;22(5):786-91. doi: 10.1097/IGC.0b013e31825104f4.

PMID:
22552832
19.

Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.

Lee J, Curtin JP, Muggia FM, Pothuri B, Boyd LR, Blank SV.

Cancer Chemother Pharmacol. 2018 Jul;82(1):55-63. doi: 10.1007/s00280-018-3591-y. Epub 2018 Apr 27.

PMID:
29704010
20.

Supplemental Content

Support Center